ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
14 announcements with these filters
GSK Pharma's postal ballot approved Ms. Natland as NED and Mr. Akshikar's MD re-appointment. Both resolutions cleared with over 99% shareholder support.
GlaxoSmithKline Pharmaceuticals issued a corrigendum for its August 3, 2026, postal ballot notice, correcting a typographical error in a reported salary figure.
GlaxoSmithKline Pharmaceuticals clarified that recent trading volume increases are purely market-driven. The company confirmed all material disclosures have been made according to SEBI regulations.
GlaxoSmithKline Pharmaceuticals received an income tax refund intimation of Rs 4.99 Crore for the assessment year 2025-2026.
GlaxoSmithKline Pharmaceuticals has issued a Postal Ballot notice for shareholder approval. The resolutions involve appointing Karine J F Natland and re-appointing Bhushan Akshikar as Managing Director.
GlaxoSmithKline Pharmaceuticals received a ₹52.00 Crore tax refund plus ₹42.09 Crore interest income following a favorable CIT-Appeal order for assessment year 1984-85.
GSK India delivered resilient FY26 results with double-digit EBITDA and PAT growth, despite muted 2% revenue growth due to significant supply disruptions from a CMO fire and vaccine shipment delays.
GSK reported muted 2% revenue growth due to supply chain disruptions at a key CMO, but delivered record-high EBITDA margins of 35% through cost optimization and a shift toward high-margin specialty products.
GSK Pharmaceuticals reported the resignation of Director Subesh Williams and the re-appointment of Executive Director Bhushan Akshikar effective December 1, 2026.
GSK India reported Q1 FY27 financial results with revenue at INR 924 crore and PAT at INR 253 crore. The company highlights growth across key therapeutic portfolios.
GSK India delivered strong Q1 FY27 standalone performance with revenue growing 15% and PAT up 24%, driven by portfolio transformation and core brand leadership.
GlaxoSmithKline Pharmaceuticals Ltd reported revenue from operations of ₹938.4 Cr (+16.5% YoY) and net profit of ₹237.2 Cr (+15.7% YoY) for Q1 FY27.
GlaxoSmithKline Pharmaceuticals Ltd scheduled a board meeting for August 3, 2026. The board will consider and approve un-audited financial results for Q1 ended June 30, 2026.
GLAXOSMITHKLINE PHARMACEUTICALS disclosed its shareholding pattern as per regulatory requirements. No monetary or transactional event was announced.